Table 2.
Treatment response by the study site and study drug
| Site/drug/number enrolled | Day 3 positive, n (%) | Non-PCR corrected | PCR corrected | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loss | LCF | LPF | ACPR, n (%) | Loss | LCF | LPF | ACPR, n (%) | ||
| Kachin/AL/56 | 2 (3.6) | 2 | 0 | 2 | 52 (96.3) | 3 | 0 | 1 | 52 (98.1) |
| Kachin/DP/56 | 0 (0) | 0 | 0 | 0 | 56 (100) | 0 | 0 | 0 | 56 (100) |
| Rakhine/AL/70 | 0 (0) | 0 | 0 | 0 | 70 (100) | 0 | 0 | 0 | 70 (100) |
| Rakhine/DP/57 | 0 (0) | 0 | 1 | 0 | 56 (98.2) | 1 | 0 | 0 | 56 (100) |
| Shan/AL/60 | 2 (3.3) | 2 | 0 | 2 | 56 (96.6) | 2 | 0 | 2 | 56 (96.6) |
| Shan/DP/60 | 0 (0) | 0 | 0 | 0 | 60 (100) | 0 | 0 | 0 | 60 (100) |
ACPR = adequate clinical and parasitological response; AL = artemether–lumefantrine; DP = dihydroartemisinin–piperaquine; LCF = late clinical failure; loss = lost to follow-up or excluded; LPF = late parasitological failure.